Uncategorized

Lilly and Resilience invest $750M in diabetes and obesity drug device supply

Published

on

The investment will expand Resilience’s U.S. capacity to make the KwikPen device Eli Lilly uses to deliver its injectable diabetes and obesity medicines.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version